Global pharma major Lupin Limited has launched Dasatinib Tablets (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg) in the United States after receiving U.S. FDA approval for its Abbreviated New Drug Application (ANDA). The tablets are bioequivalent to Sprycel® (Bristol-Myers Squibb) and target Philadelphia chromosome-positive leukemia.
Show moreStay Ahead – Explore Now! Styrenix Performance Materials Declares Dividend, Reports Q3 Results
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
